Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma

Abstract

BackgroundThe prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.MethodsUsing tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.ResultsCancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.ConclusionsThis study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib

“…Our results confirm the association of C allele in mRCC patients with higher mRNA expression levels, thereby expecting an increase in protein level. This presumption is supported by the correlation of high COX2 protein levels with shorter progression-free and cancer-specific survival in clear cell RCC23 and it is in agreement with the known role of COX2 in cancer24.…”

Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma

“…COX2 is expressed in human renal cell carcinoma tissues 36 37 and is associated with tumor cell proliferation and progression-free survival 37 38 . In the present study, free and PC-incorporating PUFAs were present in lower concentrations in the ccRCC samples compared with their levels in the normal renal cortex.…”

Retrospective evaluation ofCOX‐2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy

“…The chemoprevention properties of COX‐2 inhibitors in human oncology is a current area of interest as COX‐2/prostaglandin E2 signalling pathways may play an essential role in conferring neoplastic malignancy by enhancing cell proliferation, cell survival and tumour invasion. Anti‐COX‐2 molecules have been used for treatment of human CCRCC with some success . Knowing that CRCC express COX‐2 and that there is a link between expression and outcome, exploring the potential role of these molecules in CRCC adjuvant treatment would be required to establish its potential outcome benefit for cases with a high COX‐2 IHS expression.…”

“…Treatment with COX‐2 inhibitors has demonstrated biological activity against some canine cancers, such as urinary bladder transitional cell carcinoma or inflammatory mammary carcinoma . COX‐2 expression is a poor prognostic indicator in human CCRCC, and its expression is also correlated with tumour angiogenesis, suggesting that COX‐2 inhibition is a potential therapy requiring further investigation . Exploring the potential association of COX‐2 expression with biological behaviour in CRCC would be useful to determine whether there may be a potential role for COX‐2 inhibition in the treatment of CRCC.…”